Abstract: Polar lipid composition of plant origin for conveying an active agent and/or making it penetrate into a target cell, the composition being characterized in that it is comprised of an injectable, intra-articular, topical or ingestable aqueous emulsion of a polar lipid mixture rich in phospholipids, in glycolipids and in ceramides, having a composition which is substantially similar to that of the polar lipids constituents of lipid cytomembranes of cells and obtained from a plant compound such as cereal flour or an extract such as bran or lipids extracted from cereals by means of chlorinated solvants.

Abstract: The invention concerns compounds of general formula (I) ##STR1## in which R.sub.1 represents a methyl group, X.sub.1 represents a hydrogen atom, or OR.sub.1 and X.sub.1 together form a group of formula --O(CH.sub.2).sub.2 --,--O(CH.sub.2).sub.3 --, --O(CH.sub.2).sub.2 O-- or --O(CH.sub.2).sub.3 O--, X.sub.2 represents a hydrogen atom or an amino group, and X.sub.3 representing a halogen atom. The compounds are ligands of serotoninergic receptors of the 5-HT.sub.3 and/or 5-HT.sub.4 types, and act as 5-HT.sub.4 agonists and/or 5-HT.sub.3 antogonists.

Abstract: The pump (10) has variable volume means (24) co-operating with a distinct volume (20) through which the blood flows for the purpose of varying said volume (20) through which the blood flows in cyclical and controlled manner. According to the invention, the control circuit for the pump comprises: means for sensing data representative of aortic pressure (P(t)); means for sensing data representative of venous oxygen concentration (PO.sub.2V); means for sensing data representative of aortic oxygen concentration (PO.sub.2A); means for sensing data representative of heartbeat frequency (F); and/or means for sensing data representative of the myocardial contractility (dP/dt). The circuit can control the rates (u(t), v(t)) at which said volume varies during the systolic and diastolic phases of the myocardium, and also the instants (t.sub.A ; t.sub.R) at which said variation of the volume starts during the systolic and diastolic phases.

Abstract: The subject of the invention is indolin-2-one derivatives of formula: ##STR1## in which: W represents a --CH.sub.2 -- or --SO.sub.2 -- group;Cy forms, with the carbon to which it is bonded, a non-aromatic, saturated or unsaturated C.sub.3 -C.sub.12 hydrocarbon ring which is optionally condensed or substituted by one or a number of (C.sub.1 -C.sub.7)alkyl groups, it being possible for the said groups to substitute the same carbon atom one or a number of times, or by a C.sub.3 -C.sub.6 spirocycloalkyl;T represents a (C.sub.1 -C.sub.4)alkylene which is optionally interrupted by a (C.sub.3 -C.sub.6)cycloalkylene, the said alkylenes optionally being substituted one or a number of times on the same carbon atom by a (C.sub.1 -C.sub.3)alkyl; or alternatively T represents a direct bond;Z represents in particular an amino group;R.sub.1 and R.sub.2, as well as R.sub.3 and R.sub.4, are either hydrogen or substituents, such as, for example, a halogen, an alkyl, and the like.

Abstract: The invention relates to a process for manufacturing an injection device of the pre-filled type comprising producing, in a deformable plastics material, a tubular syringe body (101) equipped with an external locking element (104) suitable for deforming radially between retracted and dilated positions, producing a tubular sheath (109) equipped with an internal locking element (110, 111) paired with that of the syringe body (101), fitting the sheath (109) round the syringe body (101), by a relative sliding of these latter permitted by the radial retraction of the locking element (104) of the syringe body (101), and introducing into the syringe body (101) a rigid pre-filled container suitable for bringing the locking element (104) of the said syringe body into its dilated position, enabling an irreversible locking of the sheath (109) to be obtained once it has been brought, after injection, into an advanced, post-use protection position.

Abstract: The pump comprises: an essentially rigid body open at both ends and designed to be inserted in the down aorta artery; a flexible and elastic membrane (18) in the form of a sleeve connected in sealed manner to the body at the periphery of the ends thereof so as to define firstly, between the body and the sleeve, a closed intermediate space (20) of variable volume, and secondly, inside the sleeve, a variable volume (22) through which the blood to be pumped passes; and means for connecting the intermediate space to a source of hydraulic fluid suitable for causing the membrane to pass from a free state to a tensioned state in which it is urged radially inwards, thereby correspondingly reducing the volume through which the blood passes, and vice versa.

Abstract: A pump comprises variable volume means inserted in an artery, in particular, the descending aorta, enabling the volume through which the blood flows in this location to be modified cyclically and in a controlled manner. The device comprises a deformable enclosure in fluid communication with the variable volume. The variable volume and a spring coil urge the deformable enclosure against an increase of volume resulting from a pressure increase in the variable volume, and in the corresponding enclosure, in a way which produces additional elastance for the artery during the heart cycle. In addition, an electric motor can control the deformable enclosure to increase or decrease its volume, and can exert its force in addition to or in subtraction from the force of the spring coil during the systolic and diastolic phases of the heart cycle. This produces an additional pumping effect on arterial blood and correspondingly relieves the effort required of the heart.

Abstract: Compounds of formula (I), a method for obtaining them and pharmaceutical compositions containing them are described. The compounds are useful as human NK.sub.3 receptor antagonists.

Abstract: Compounds of formula (I), wherein R.sub.1 is fluorine, hydroxy, (C.sub.1-5) alkoxy, (C.sub.1-5) alkylthio, hydroxy(C.sub.1-5)alkoxy, a -NR.sub.10 R.sub.11, group, cyano, (C.sub.1-5) alkyl-sulphonyl or (C.sub.1-5) alkylsulphinyl; R.sub.2 and R.sub.3 are each (C,.sub.4) alkyl or, taken together with the nitrogen atom to which they are attached, form a saturated or unsaturated 5- to 10-membered heterocyclic radical optionally substituted one or more times by (C.sub.1-3) alkyl or (C.sub.1-3) alkoxy; each of R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8 and R.sub.9 is independently hydrogen, halogen or trifluoromethyl, and when R.sub.1 is fluorine, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8 and/or R.sub.9 may also be fluoromethyl; with the proviso that at least one of substituents R.sub.4 or R.sub.7. is other than hydrogen; each of R.sub.10 and R.sub.11 is independently hydrogen or (C.sub.1-5) alkyl, or R.sub.10 and R.sub.

Abstract: The use of polyamine site antagonists in treating ischemic disorders of the retina and optic nerve head are disclosed. Especially preferred are certain 1-phenyl-2-piperidinoalkanol derivatives, such as eliprodil and ifenprodil.

Abstract: The invention relates to compounds of formula ##STR1## in which R.sub.1 to R.sub.9, R.sub.16 and R.sub.17 are defined in claim 1. These compounds are pharmacologically active.

Abstract: Substituted N-arylmethyl and heterocyclylmethyl-1H-pyrazolo[3,4-b]quinolin-4-amines, pharmaceutical compositions containing them and methods for a) effecting c-GMP-phosphodiesterase inhibition, b) treating heart failure and/or hypertension, c) reversing or reducing nitrate-induced tolerance and d) treating angina pectoris, congestive heart disease and myocardial infarction utilizing them.

Abstract: The invention relates to glutarimides of formula (I): ##STR1## in which Ar represents a phenyl non substituted or substituted one or more times with one of the substitutents selected from a halogen atom, a hydroxyl, a (C.sub.1 -C.sub.4)alkoxy, a trifluoromethyl, a (C.sub.1 -C.sub.4)alkyl, said substitutents being identical or different ; a pyridyl group; a thienyl group and X is methylene or ethylene, their salts and their enantiomers, as well as their method of preparation and their use for the preparation of the corresponding 3,3-disubstituted piperidines.

Abstract: The subject of the invention is indolin-2-one derivatives of formula: ##STR1## in which: W represents a --CH.sub.2 -- or --SO.sub.2 -- group;Cy forms, with the carbon to which it is bonded, a non-aromatic, saturated or unsaturated C.sub.3 -C.sub.12 hydrocarbon ring which is optionally condensed or substituted by one or a number of (C.sub.1 -C.sub.7)alkyl groups, it being possible for the said groups to substitute the same carbon atom one or a number of times, or by a C.sub.3 -C.sub.6 spirocycloalkyl;T represents a (C.sub.1 -C.sub.4)alkylene which is optionally interrupted by a (C.sub.3 -C.sub.6)cycloalkylene, the said alkylenes optionally being substituted one or a number of times on the same carbon atom by a (C.sub.1 -C.sub.3)alkyl; or alternatively T represents a direct bond;Z represents in particular an amino group;R.sub.1 and R.sub.2, as well as R.sub.3 and R.sub.4, are either hydrogen or substituents, such as, for example, a halogen, an alkyl, and the like.

Abstract: Compounds derived from oxazolidin-2-one of formula (I) ##STR1## in which: R.sub.1 represents a hydrogen atom, an alkyl group, a hydroxyalkyl group, a fluoroalkyl group, a hydroxyfluoroalkyl group, a cyanoalkyl group, a substituted or unsubstituted phenyl group, a substituted or unsubstituted phenylmethyl group or an R.sub.3 A- group in which R.sub.3 is a cycloalklyl or cyclooxyalkyl group which is unsubstituted or substituted by a hydroxyl group and A is a --CH.sub.2 or --CH.sub.2 --CH.sub.2 radical,R.sub.2 represents a hydrogen atom or a methyl group,X represents an oxygen or sulphur atom or an NR.sub.4 group where R.sub.4 is an alkyl group or a hydrogen atom, andZ represents an oxygen atom or a --CH.dbd.CH or --CH.sub.2 --CH.sub.2 group,their process of preparation and their applications in therapeutics.

Abstract: Compounds of formula (I) ##STR1## in which A represents a 4-(thieno?3,2-c! pyridin-4-yl)-1-piperazinyl or 4-(4-fluorobenzoyl)-1-piperidyl group, R.sub.1 and R.sub.2 each represent, independently of one another, either a hydrogen or halogen atom, or an amino, hydroxyl, nitro, cyano, (C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.6)alkoxy, trifluoromethyl, trifluoromethoxy or --COOH group, a group --COOR.sub.4, a --CONH.sub.2 group or a group --CONHR.sub.4, --CONR.sub.4 R.sub.5, --SR.sub.4, --SO.sub.2 R.sub.4, --NHCOR.sub.4, --NHS0.sub.2 R.sub.4 or --N(R.sub.4).sub.2, where R.sub.4 and R.sub.5 are each a (C.sub.1 -C.sub.4)alkyl group, R.sub.3 represents either a hydrogen atom, or a (C.sub.1 -C.sub.4)alkyl group, or a group --(CH.sub.2)OH, --(CH.sub.2).sub.p NH.sub.2, --(CH.sub.2).sub.n COOH, --(CH.sub.2).sub.n COOR.sub.4, --(CH.sub.2).sub.n CONH.sub.2, --(CH.sub.2).sub.n CONHOH, --(CH.sub.2).sub.p SH, --(CH.sub.2).sub.n SO.sub.3 H, --(CH.sub.2).sub.n SO.sub.2 NH.sub.2, --(CH.sub.2).sub.n SO.sub.2 NHR.sub.4, --(CH.

Abstract: Compounds corresponding to the general formula (I) ##STR1## in which R.sub.1 represents a (C.sub.1 -C.sub.4)alkyl or (C.sub.3 -C.sub.7)cycloalkylmethyl group, X.sub.1 represents a hydrogen or halogen atom or a (C.sub.1 -C.sub.4)alkoxy group or else OR.sub.1 and X.sub.1 together represent a group of formula -OCH.sub.2 O-, -O(CH.sub.2).sub.2 -, -O(CH.sub.2).sub.3 -, -O(CH.sub.2).sub.2 O- or -O(CH.sub.2).sub.3 O-, X.sub.2 represents a hydrogen atom or an amino group, X.sub.3 represents a hydrogen or halogen atom, and R.sub.2 represents either a hydrogen atom or an optionally substituted (C.sub.1 -C.sub.6) alkyl group or a phenyl (C.sub.1 -C.sub.4) alkyl group which is optionally substituted on the phenyl ring or a phenyl (C.sub.2 -C.sub.3) alkenyl group or a phenoxy (C.sub.2 -C.sub.4) alkyl group or a cyclo (C.sub.3 -C.sub.7) alkylmethyl group or a 2,3-dihydro-1H-inden-1-yl or 2,3-dihydro-1H-inden-2-yl group or a group of general formula -(CH.sub.2).sub.

Abstract: Compounds corresponding to the general formula (I): ##STR1## in which X represents a hydrogen atom, a hydroxyl group, a C.sub.1 -C.sub.3 alkoxy group or a cyclopropylmethoxy group and Y represents a hydrogen atom, a hydroxyl group or a methoxy group and salts and bases thereof. The compounds may exists in the form of a pure enantiomer or as a mixture of enantiomers. Additionally, the compounds of formula (I) are useful for the treatment of diseases associated with serotoninergic receptors, particularly anxiety and/or depression.